Cargando…

Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma

OBJECTIVE: Programmed death-ligand 1 (PD-L1) was expressed in various tumors and antibodies targeting its receptor programmed cell death-1 (PD-1) are emerging cancer therapeutics. This study was designed to evaluate the expression of PD-L1 and its correlation with clinicopathologic features and clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jun, Wen, Hao, Bi, Rui, Wu, Yong, Wu, Xiaohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641527/
https://www.ncbi.nlm.nih.gov/pubmed/29027395
http://dx.doi.org/10.3802/jgo.2017.28.e77
_version_ 1783271239858520064
author Zhu, Jun
Wen, Hao
Bi, Rui
Wu, Yong
Wu, Xiaohua
author_facet Zhu, Jun
Wen, Hao
Bi, Rui
Wu, Yong
Wu, Xiaohua
author_sort Zhu, Jun
collection PubMed
description OBJECTIVE: Programmed death-ligand 1 (PD-L1) was expressed in various tumors and antibodies targeting its receptor programmed cell death-1 (PD-1) are emerging cancer therapeutics. This study was designed to evaluate the expression of PD-L1 and its correlation with clinicopathologic features and clinical outcomes in ovarian clear cell carcinoma (OCCC). METHODS: The PD-L1 expression was measured by tissue-microarray-based immunohistochemistry from 122 eligible patients diagnosed with OCCC. The associations of clinicopathologic features with progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier method and multivariate analysis was further performed by Cox regression model. RESULTS: Overall, high PD-L1 expression (PD-L1(high)) was observed in 44.7% (55/123) of OCCC patients, and was strongly associated with advanced stages (p=0.020), positive ascitic fluid (p=0.016), platinum-resistant (PR) disease (p=0.045), and recurrence (p=0.038). Moreover, patients with PD-L1(high) were associated with poorer OS (hazard ratio [HR]=2.877; p=0.001) and PFS (HR=1.843; p=0.021) than those with low PD-L1 expression (PD-L1(low)). In subgroup analysis, PD-L1(high) patients experienced a poorer PFS (HR=1.926; p=0.044) and OS (HR=2.492; p=0.021) than PD-L1(low) cases among advanced stages (III–IV), but this difference was not observed in stage I–II patients. Meanwhile, PD-L1(high) was associated with poorer prognosis than PD-L1(low) in PR patients (OS, HR=2.253; p=0.037; PFS, HR=1.448; p=0.233). Multivariate analysis revealed that PD-L1(high) and advanced stages (III–IV) were adverse independent prognosticators for both PFS (HR(PD-L1)=2.0; p(PD-L1)=0.038; HR(stage)=10.2; p(stage)<0.001) and OS (HR(PD-L1)=3.0; p(PD-L1)=0.011; HR(stage)=14.3; p(stage)<0.001). CONCLUSION: PD-L1(high) might serve as a risk factor for PFS and OS in patients with OCCC. It is possible that immunotherapy targeting PD-L1 pathway could be used in OCCC.
format Online
Article
Text
id pubmed-5641527
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology
record_format MEDLINE/PubMed
spelling pubmed-56415272017-11-01 Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma Zhu, Jun Wen, Hao Bi, Rui Wu, Yong Wu, Xiaohua J Gynecol Oncol Original Article OBJECTIVE: Programmed death-ligand 1 (PD-L1) was expressed in various tumors and antibodies targeting its receptor programmed cell death-1 (PD-1) are emerging cancer therapeutics. This study was designed to evaluate the expression of PD-L1 and its correlation with clinicopathologic features and clinical outcomes in ovarian clear cell carcinoma (OCCC). METHODS: The PD-L1 expression was measured by tissue-microarray-based immunohistochemistry from 122 eligible patients diagnosed with OCCC. The associations of clinicopathologic features with progression-free survival (PFS) and overall survival (OS) were analyzed by Kaplan-Meier method and multivariate analysis was further performed by Cox regression model. RESULTS: Overall, high PD-L1 expression (PD-L1(high)) was observed in 44.7% (55/123) of OCCC patients, and was strongly associated with advanced stages (p=0.020), positive ascitic fluid (p=0.016), platinum-resistant (PR) disease (p=0.045), and recurrence (p=0.038). Moreover, patients with PD-L1(high) were associated with poorer OS (hazard ratio [HR]=2.877; p=0.001) and PFS (HR=1.843; p=0.021) than those with low PD-L1 expression (PD-L1(low)). In subgroup analysis, PD-L1(high) patients experienced a poorer PFS (HR=1.926; p=0.044) and OS (HR=2.492; p=0.021) than PD-L1(low) cases among advanced stages (III–IV), but this difference was not observed in stage I–II patients. Meanwhile, PD-L1(high) was associated with poorer prognosis than PD-L1(low) in PR patients (OS, HR=2.253; p=0.037; PFS, HR=1.448; p=0.233). Multivariate analysis revealed that PD-L1(high) and advanced stages (III–IV) were adverse independent prognosticators for both PFS (HR(PD-L1)=2.0; p(PD-L1)=0.038; HR(stage)=10.2; p(stage)<0.001) and OS (HR(PD-L1)=3.0; p(PD-L1)=0.011; HR(stage)=14.3; p(stage)<0.001). CONCLUSION: PD-L1(high) might serve as a risk factor for PFS and OS in patients with OCCC. It is possible that immunotherapy targeting PD-L1 pathway could be used in OCCC. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017-11 2017-08-18 /pmc/articles/PMC5641527/ /pubmed/29027395 http://dx.doi.org/10.3802/jgo.2017.28.e77 Text en Copyright © 2017. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Zhu, Jun
Wen, Hao
Bi, Rui
Wu, Yong
Wu, Xiaohua
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
title Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
title_full Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
title_fullStr Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
title_full_unstemmed Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
title_short Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma
title_sort prognostic value of programmed death-ligand 1 (pd-l1) expression in ovarian clear cell carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641527/
https://www.ncbi.nlm.nih.gov/pubmed/29027395
http://dx.doi.org/10.3802/jgo.2017.28.e77
work_keys_str_mv AT zhujun prognosticvalueofprogrammeddeathligand1pdl1expressioninovarianclearcellcarcinoma
AT wenhao prognosticvalueofprogrammeddeathligand1pdl1expressioninovarianclearcellcarcinoma
AT birui prognosticvalueofprogrammeddeathligand1pdl1expressioninovarianclearcellcarcinoma
AT wuyong prognosticvalueofprogrammeddeathligand1pdl1expressioninovarianclearcellcarcinoma
AT wuxiaohua prognosticvalueofprogrammeddeathligand1pdl1expressioninovarianclearcellcarcinoma